BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 3896482)

  • 1. Autologous bone marrow transplantation with marrow decontaminated by immunotoxin T 101 in the treatment of leukemia and lymphoma: first clinical observations.
    Gorin NC; Douay L; Laporte JP; Lopez M; Zittoun R; Rio B; David R; Stachowiak J; Jansen J; Cazellas P
    Cancer Treat Rep; 1985 Sep; 69(9):953-9. PubMed ID: 3896482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Autograft of bone marrow treated by immunotoxin T 101 for the treatment of T-cell leukemia and lymphoma. Initial clinical cases].
    Gorin NC; Douay L; Laporte JP; Lopez M; Zittoun R; Rio B; Najman A; Jansen FK; Voisin GA; Stachowiak J
    Presse Med; 1985 Nov; 14(37):1909-13. PubMed ID: 2933692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Grossbard ML; Multani PS; Freedman AS; O'Day S; Gribben JG; Rhuda C; Neuberg D; Nadler LM
    Clin Cancer Res; 1999 Sep; 5(9):2392-8. PubMed ID: 10499609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K; Margolin K; Champlin R; Forman S
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial of high-dose cytarabine, cyclophosphamide, total-body irradiation, and autologous marrow transplantation for refractory lymphoma.
    Armitage JO; Gingrich RD; Klassen LW; Bierman PJ; Kumar PP; Weisenburger DD; Smith DM
    Cancer Treat Rep; 1986 Jul; 70(7):871-5. PubMed ID: 3521847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease.
    Antin JH; Bierer BE; Smith BR; Guinan EC; Provost MM; Ferrara J; Macklis RM; Tarbell NJ; Blythman H; Bouloux C
    Prog Clin Biol Res; 1990; 333():207-15. PubMed ID: 1689852
    [No Abstract]   [Full Text] [Related]  

  • 7. Preliminary clinical trial of autologous bone marrow transplantation after in vitro monoclonal antibody and complement treatments in null cell-type acute lymphocytic leukemia.
    Morishima Y; Sao H; Ueda R; Morishita Y; Murase T; Kodera Y; Ohno R; Tahara T; Yoshikawa S; Kato Y
    Jpn J Cancer Res; 1985 Dec; 76(12):1222-9. PubMed ID: 3937834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged disease-free survival after ablative chemoradiotherapy and autologous bone marrow transplantation in adult malignant lymphoma.
    Da WM; Zhong JT; Liu Y; Huang YS; Bai H; Wu XX; Ou YX; Wang CB; Xu SF
    Chin Med J (Engl); 1993 Apr; 106(4):277-81. PubMed ID: 8325155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined ex vivo treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts.
    Uckun FM; Stong RC; Youle RJ; Vallera DA
    J Immunol; 1985 May; 134(5):3504-15. PubMed ID: 3884712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Difference in kinetics of hematopoietic reconstitution between ALL and ANLL after autologous bone marrow transplantation with marrow treated in vitro with mafosfamide (ASTA Z 7557).
    Douay L; Laporte JP; Mary JY; Lopez M; Lemonnier MP; Stachowiak J; Benitez O; Deloux J; Najman A; Salmon C
    Bone Marrow Transplant; 1987 Jun; 2(1):33-43. PubMed ID: 3332155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
    Longo DL; Duffey PL; Gribben JG; Jaffe ES; Curti BD; Gause BL; Janik JE; Braman VM; Esseltine D; Wilson WH; Kaufman D; Wittes RE; Nadler LM; Urba WJ
    Cancer J; 2000; 6(3):146-50. PubMed ID: 10882329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous transplantation of bone marrow purged in vitro with anti-CD7-(WT1-) ricin A immunotoxin in T-cell lymphoblastic leukemia and lymphoma.
    Preijers FW; De Witte T; Wessels JM; De Gast GC; Van Leeuwen E; Capel PJ; Haanen C
    Blood; 1989 Aug; 74(3):1152-8. PubMed ID: 2473811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous bone-marrow transplantation for Burkitt's lymphoma: marrow purging with anti-Y 29/55 monoclonal antibody and complement.
    Baumgartner C; Delaleu B; Imbach P; Lüthy A; Odavic R; Brun del Re G; Bucher U; Forster HK; Hirt A; Wagner HP
    IARC Sci Publ; 1985; (60):435-40. PubMed ID: 3905594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for absence of toxicity of T101 immunotoxin on human hematopoietic progenitor cells prior to bone marrow transplantation.
    Douay L; Gorin NC; Lopez M; Casellas P; Liance MC; Jansen FK; Voisin GA; Baillou C; Laporte JP; Najman A
    Cancer Res; 1985 Jan; 45(1):438-41. PubMed ID: 3880666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse.
    Soiffer RJ; Roy DC; Gonin R; Murray C; Anderson KC; Freedman AS; Rabinowe SN; Robertson MJ; Spector N; Pesek K
    Bone Marrow Transplant; 1993 Sep; 12(3):243-51. PubMed ID: 8241984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous bone marrow transplantation for B cell malignancies after in vitro purging with floating immunobeads.
    Stoppa AM; Hirn J; Blaise D; Delaage M; Novakovitch G; Viens P; Capiello MA; Mannoni P; Mawas C; Maraninchi D
    Bone Marrow Transplant; 1990 Nov; 6(5):301-7. PubMed ID: 2291992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue.
    Lu C; Braine HG; Kaizer H; Saral R; Tutschka PJ; Santos GW
    Cancer Treat Rep; 1984 May; 68(5):711-7. PubMed ID: 6373004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
    Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W
    Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.